The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

Sanofi-Aventis' Merilog version of the product has been cleared for the treatment of adult and paediatric patients with type 2 diabetes. It is the first biosimilar of a rapid-acting insulin ...

The product, called Merilog, is the first fast-acting insulin biosimilar to get a federal nod. Biosimilars are near-identical versions of FDA-approved biologic drugs, offering the same safety and ...

FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes By Stephanie Brown HealthDay Reporter WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug ...

WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...

WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...

As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes. The approval is for both a 3 milliliter (mL) single-patient ...

Moderna’s norovirus vaccine trial was put on hold by the agency over neurological side effects. Sanofi and Aventis’ merilog injection was approved by the agency. PTC Therapeutics announced FDA ...